What is BPC-157? BPC-157 is a synthetic peptide made of 15 amino acids. It has become one of the most frequently studied research peptides of the last two decades. This overview covers what the BPC-157 research literature contains, what it does not show, and the practical points researchers usually ask about.
What is BPC-157? At a glance
| Full name | Body Protection Compound 157 |
|---|---|
| Type | Synthetic pentadecapeptide (15 amino acids) |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular weight | Approximately 1,419 Da |
| Common salt forms | Acetate and arginate (often labelled “BPC-157 Arg”) |
| Regulatory status | Not approved as a medicine; prohibited in sport by WADA |
Where the BPC-157 peptide comes from
BPC-157 is a partial sequence of a larger protein first described in human gastric juice. That parent protein gave the compound its name, “body protection compound”. The 15-residue fragment studied today is produced by solid-phase peptide synthesis and supplied as a lyophilised (freeze-dried) powder.
Most of the early work came from a single research group at the University of Zagreb, which has published on the peptide since the early 1990s. Other laboratories have since added to the literature, but a large share of the published papers still come from that group. Reviewers often point this out when they assess the evidence.
What BPC-157 research has examined
The great majority of BPC-157 research is preclinical, meaning it was carried out in cell cultures and animal models, mainly rats and mice. The main themes in the literature are listed below. A PubMed search for BPC-157 returns the full list of indexed papers.
Gastrointestinal models
Given its gastric origin, the peptide was first studied in rodent models of stomach and intestinal lesions. Researchers looked at mucosal integrity and at how the compound interacts with other agents in these models.
Tendon, ligament and muscle models
A second group of studies used rodent models of tendon, ligament and skeletal muscle injury. Researchers measured outcomes such as tissue organisation and functional recovery after controlled injuries.
Blood vessel formation and signalling
Mechanistic papers have explored angiogenesis (the formation of new blood vessels), the nitric oxide system and growth-factor signalling pathways. These studies help explain why the peptide shows up in so many different experimental models.
What the research does not show
Controlled human data are very limited. Published human reports are small and preliminary, and there are no large randomised clinical trials. Results from animal models do not reliably predict effects in people, which is why BPC-157 remains a research compound and not an approved therapy.
BPC-157 stability and handling
One reason BPC-157 is a popular research tool is its reported stability. Studies describe it as unusually stable in gastric juice compared with many peptides. Even so, it should be handled like any other research peptide:
- store the lyophilised powder cold, dry and away from light;
- reconstitute it with a suitable sterile diluent using aseptic technique;
- refrigerate reconstituted solutions and avoid repeated freeze–thaw cycles.
Our step-by-step guide to reconstituting research peptides covers diluent choice, concentration calculations and storage in more detail.
BPC-157 vs TB-500
BPC-157 is often discussed alongside TB-500. TB-500 is the name commonly used for a synthetic peptide based on the active region of thymosin beta-4, a naturally occurring protein involved in cell migration and actin regulation. The two compounds are unrelated in structure:
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Fragment of a gastric protein | Based on thymosin beta-4 |
| Length | 15 amino acids | Short fragment (commonly residues 17–23 region) |
| Main research themes | GI, tendon and vascular models | Cell migration and actin-binding models |
Because their research themes overlap, some laboratories study them together. That is why pre-combined products such as the BPC-157 + TB-500 blend exist.
Regulation and sport
BPC-157 is not approved as a medicine in the United States, the UK or the EU. The World Anti-Doping Agency includes it on its Prohibited List under non-approved substances. The US FDA has also listed BPC-157 among the bulk drug substances that may present significant safety risks in compounding. These positions reinforce that BPC-157 belongs in the laboratory, not in human use.
BPC-157 formats for research
Pure Rawz supplies BPC-157 research peptide as a lyophilised powder in several vial sizes. It is also available as BPC-157 capsules, a BPC-157 spray and the arginate salt form. Browse the full research peptides range to compare them.
Key takeaways
- BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protein.
- Most BPC-157 research is preclinical, and human evidence remains limited.
- It is regarded as relatively stable but still needs proper cold, dry storage.
- It is not an approved medicine and is prohibited in sport.
Looking for more background reading? Visit the Pure Rawz research blog or contact our team with product questions.
Research use only. This article summarises published research for educational purposes. It is not medical advice. Products sold by Pure Rawz are intended for laboratory research only and are not for human or animal consumption.